Acacia Research Corporation reported Q4 2024 revenue of $48.8 million, driven by acquisitions in the energy and manufacturing sectors. Despite this, the company posted a net loss of $13.4 million. Adjusted EBITDA was positive at $4.9 million, reflecting operational improvements and cost efficiencies.
Acacia Research Corporation reported a significant increase in consolidated revenue, up 131% year-over-year, driven by strong performance in its energy and industrial operations. However, the company recorded a net loss for the quarter, while also generating positive Adjusted EBITDA and making a strategic acquisition post-quarter.
Acacia Research Corporation reported a significant increase in consolidated revenue for Q2 2024, up 227% compared to Q2 2023, driven by the acquisition of operated producing wells. The company remains focused on free cash flow generation and book value per share accretion.
Acacia Research reported consolidated revenue of $24.3 million for the quarter, compared to $14.8 million in the first quarter of 2023. The company had a GAAP net loss of $0.2 million, or $0.00 per share. They also completed the sale of Acacia’s shares of Arix Bioscience Plc for a cash purchase price of $57.1 million.
Acacia Research Corporation reported a significant increase in total revenues for Q4 2023, primarily driven by its Intellectual Property business. The company also saw an increase in operating income and GAAP net income compared to the same quarter last year.
Acacia Research Corporation reported consolidated revenue of $10.1 million for the quarter, a decrease compared to $15.9 million in the third quarter of 2022. The company recorded $12.2 million of net realized and unrealized gains during the quarter and a GAAP net income of $1.6 million, or a net loss of $0.03 per diluted share.
Acacia Research Corporation reported a consolidated revenue of $7.9 million for the quarter, compared to $16.7 million in the same quarter of the previous year. The company experienced an operating loss of $12.5 million and a GAAP net loss of $18.8 million, or $0.36 per diluted share.
Acacia Research Corporation reported consolidated revenue of $14.8 million for the quarter, compared to $13.5 million in the first quarter of 2022. The company recorded a GAAP net income of $9.4 million, compared to a net loss of $73.3 million in the same quarter last year.
Acacia Research reported a decrease in consolidated revenue to $13.1 million for the quarter, compared to $63.3 million in the same quarter last year. The company completed an agreement to streamline its capital structure and navigate changes to its executive team. They enter 2023 with the right structure and organization and are well-positioned to take advantage of economic dynamics to acquire value-creating assets.
Acacia Research Corporation reported consolidated revenue of $15.9 million for the quarter, up from $1.6 million in the third quarter of 2021. The company recorded $36.1 million in realized gains from the sale of equity securities and repaid $55.0 million in Senior Secured Notes held by Starboard during the quarter. They completed a $40.0 million stock repurchase program.
Acacia Research Corporation reported a decrease in revenue to $16.7 million compared to $17.4 million in the same quarter last year. The company experienced an operating loss of $5.7 million and a GAAP net loss of $61.5 million, or $1.44 per diluted share. These results were impacted by unrealized losses on equity securities and non-cash expenses related to warrant liabilities, as well as increased general and administrative expenses.
Acacia Research reported a revenue of $13.5 million, up from $5.8 million in the same quarter last year, which includes $10.9 million from Printronix. The company experienced a GAAP Net Loss of $73.3 million, or ($1.61) per diluted share, compared to a net loss of $164.5 million, or ($2.81) per diluted share, in the first quarter of last year. The company completed $15.0 million of share repurchases and anticipates receiving a $26 million milestone payment from Mycovia Pharmaceuticals.
Acacia Research reported a significant quarter with $101 million in realized and unrealized gains from its life sciences portfolio, driven by the Oxford Nanopore IPO. The company's pro forma book value increased to $6.31 per share. Additionally, Acacia completed its first operating company acquisition, Printronix.
Acacia Research reported increased book value in Q2 2021, driven by its life science portfolio and IP investments. The company's capital base is now $770 million, and it is actively pursuing acquisitions of operating businesses.
Acacia Research reported its Q1 2021 financial results, with a focus on evaluating new strategic opportunities and ongoing IP investments. The company led the reconstitution of the Board of Directors of Arix Bioscience plc, where Acacia is a significant shareholder.
Acacia Research Corporation reported its Q4 and Full-Year 2020 financial results, with book value increasing to $292.5 million, or $5.94 per share, as of December 31, 2020. The company completed its first transaction with Starboard Value LP, acquiring a portfolio of late-stage life science assets and increasing book value by more than $117.5 million.
Acacia Research Corporation reported results for the three-month period ended September 30, 2020. The company has recovered two-thirds of the purchase price from dispositions since acquiring the Woodford portfolio in June and continues to hold substantial value in the securities of public and private companies remaining in the portfolio.
Acacia Research Corporation reported their second quarter 2020 financial results, featuring the acquisition of the Woodford portfolio of life science assets for $282 million and the recovery of $185 million through sales of certain acquired assets. The company's book value at June 30 is $164.7 million, or $3.36 per share.
Acacia Research Corporation reported its financial results for the three-month period ended March 31, 2020. The company has made significant progress in 2020, furthering its absolute return strategy with the acquisition of two attractive patent portfolios, expected to generate licensing revenues in the second quarter and significant contributions in 2021.
Acacia Research reported their Q4 2019 financial results, highlighting a substantially expanded capital base and a leaner cost structure. The company is focusing on leveraging their partnership with Starboard Value to pursue investment opportunities and grow Acacia’s book value.